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MaBACKGROUND Peripartum cardiomyopathy (PPCM) remains a major cause of maternal morbidity and mortality.
OBJECTIVES This study sought to prospectively evaluate recovery of the left ventricular ejection fraction (LVEF) and
clinical outcomes in the multicenter IPAC (Investigations of Pregnancy Associated Cardiomyopathy) study.
METHODS We enrolled and followed 100 women with PPCM through 1 year post-partum. The LVEF was assessed
by echocardiography at baseline and at 2, 6, and 12 months post-partum. Survival free from major cardiovascular events
(death, transplantation, or left ventricular [LV] assist device) was determined. Predictors of outcome, particularly
race, parameters of LV dysfunction (LVEF), and remodeling (left ventricular end-diastolic diameter [LVEDD]) at pre-
sentation, were assessed by univariate and multivariate analyses.
RESULTS The cohort was 30% black, 65% white, 5% other; the mean patient age was 30  6 years; and 88% were
receiving beta-blockers and 81% angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. The LVEF
at study entry was 0.35  0.10, 0.51  0.11 at 6 months, and 0.53  0.10 at 12 months. By 1 year, 13% had experienced
major events or had persistent severe cardiomyopathy with an LVEF <0.35, and 72% achieved an LVEF $0.50. An initial
LVEF <0.30 (p ¼ 0.001), an LVEDD $6.0 cm (p < 0.001), black race (p ¼ 0.001), and presentation after 6 weeks post-
partum (p ¼ 0.02) were associated with a lower LVEF at 12 months. No subjects with both a baseline LVEF <0.30 and an
LVEDD $6.0 cm recovered by 1 year post-partum, whereas 91% with both a baseline LVEF $0.30 and an LVEDD <6.0
cm recovered (p < 0.00001).
CONCLUSIONS In a prospective cohort with PPCM, most women recovered; however, 13% had major events or
persistent severe cardiomyopathy. Black women had more LV dysfunction at presentation and at 6 and 12 months
post-partum. Severe LV dysfunction and greater remodeling at study entry were associated with less recovery.
(Investigations of Pregnancy Associated Cardiomyopathy [IPAC]; NCT01085955) (J Am Coll Cardiol 2015;66:905–14)
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ABBR EV I A T I ON S
AND ACRONYMS
BMI = body mass index
BP = blood pressure
LV = left ventricular
LVAD = left ventricular assist
device
LVEDD = left ventricular end-
diastolic diameter
LVEF = left ventricular ejection
fraction
DLVEF = change in left
ventricular ejection fraction
PPCM = peripartum
cardiomyopathy
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906P eripartum cardiomyopathy (PPCM) isan uncommon complication of preg-nancy that remains a major cause of
maternal morbidity and mortality (1).
Although older studies estimate its preva-
lence in the United States at 1 in 4,000 live
births, with increased recognition, more
recent studies place this estimate closer to 1
in 2,000 (2). PPCM is endemic in Haiti (3)
and parts of Africa (4), and race remains aSEE PAGE 915major risk factor for its development (5,6).
The clinical presentation is similar to that of
other forms of nonischemic cardiomyopathy,with the onset in the later part of pregnancy or the
ﬁrst few months post-partum (7). Although the etiol-
ogy remains uncertain, an autoimmune inﬂammatory
pathogenesis triggered by fetal or placental antigens
has been suspected (8,9). More recently, both genetic
(10,11) and vascular (12) etiologies have been postu-
lated to play a signiﬁcant role.
Outcomes of PPCM are markedly heterogeneous.
Previous investigations have demonstrated that
many women with PPCM recover left ventricular (LV)
function completely; however, a substantial per-
centage is left with persistent dilated cardiomyopathy
and chronic progressive heart failure (13). Given the
low prevalence of the disorder, most single-center
reports are limited in study number and being retro-
spective, and there is minimal prospective data on
clinical outcomes of contemporary evidence-based
therapy (14,15). The utility of demographics or clin-
ical phenotype for predicting myocardial recovery has
not been prospectively evaluated.
The Peripartum Cardiomyopathy Network was
formed as a 30-center collaborative group to facilitate
research on this disorder. The IPAC (Investigations of
Pregnancy Associated Cardiomyopathy) study was
initiated in 2009 as a National Heart, Lung, and Blood
Institute–funded multicenter, prospective investiga-
tion of the demographic characteristics, inﬂammatory
pathogenesis, treatment, and clinical predictors of
outcomes for PPCM patients in North America. We
now report the clinical characteristics of the IPAC
cohort, the subsequent outcomes during the ﬁrst year
post-partum, and the clinical and demographic pre-
dictors of myocardial recovery.
METHODS
COHORT. Between December 2009 and September
2012, 100 women with newly diagnosed PPCM were
enrolled within the ﬁrst 13 weeks post-partum at 30centers (Online Appendix). All women were at least
18 years of age and had no history of cardiac disease, an
estimated clinical LV ejection fraction (LVEF) #0.45
at the time of enrollment, and an evaluation
consistent with idiopathic nonischemic cardiomyop-
athy. Women with signiﬁcant valvular disease, coro-
nary disease (>50% stenosis of a major epicardial
vessel or a positive noninvasive study), evidence of
ongoing bacterial septicemia (positive blood cultures),
ongoing drug or alcohol abuse, history of chemo-
therapy or chest radiationwithin 5 years of enrollment,
or a history of cardiomyopathy were excluded.
PROTOCOL. The study protocol was approved by the
institutional review boards at all participating cen-
ters, and informed consent was obtained from all
subjects. At the time of enrollment, demographic in-
formation (including self-designated race), previous
clinical evaluation, and current medical therapy were
recorded. Women were followed until 1 year post-
partum. All hospitalizations and major cardiac
events, including death, cardiac transplantation,
and implantation of a left ventricular assist device
(LVAD), were recorded.
LV FUNCTION. All subjects had an echocardiogram to
assess LVEF at the time of enrollment, which was
repeated at 6 and 12 months post-partum. Women
enrolled early (within 6 weeks post-partum, n ¼ 66)
had a repeat assessment of LV function at 2 months.
Echocardiograms were reviewed by a core laboratory
at the University of Pittsburgh for assessment
of ventricular volumes and calculation of ejection
fraction. LV volumes and LVEFs were assessed by
biplane Simpson’s rule using manual tracing of digital
images. Left ventricular end-diastolic diameter
(LVEDD) was assessed in the parasternal long-axis
view. Due to format, a subset of echocardiograms
were not available for assessment by the core labo-
ratory (22 of 310, 7%); for these studies, the LVEF
calculated locally was used.
STATISTICAL ANALYSIS. The Student t and Fisher
exact tests were used to compare continuous and
categorical variables by self-identiﬁed race (“black”
vs. “white and other”). The Kaplan-Meier method
was next used to estimate survival free from events
(cardiac transplantation and need for mechanical
circulatory support). Using the exact log-rank test,
event-free survival was compared between racial
subsets. For analysis of event rate by baseline LVEF,
an initial LVEF <0.30 delineated approximately
one-third of the cohort with the most severe
LV dysfunction on presentation (initial LVEF <0.30,
n ¼ 30), and this subset was compared with those
with moderate LV dysfunction (LVEF $0.30, n ¼ 70).
TABLE 1 Clinical Characteristics and Myocardial Recovery by Race
All
(N ¼ 100)
Black
(n ¼ 30)
White or
Other*
(n ¼ 70)
p
Value
Age, yrs 30  6 30  6 30  6 0.85
NYHA functional class
(I/II/III/IV)
12/46/25/17 20/40/33/7 9/49/21/21 0.15
% Familial 10 9 13 0.48
% With diabetes 11 17 9 0.30
% With hypertension 45 70 34 0.002
Days PP at entry, 31  24 42  25 26  22 0.002
HR, beats/min 86  16 88  13 85  18 0.36
SBP, mm Hg 112  17 116  19 110  16 0.09
DBP, mm Hg 71  13 76  12 68  13 0.009
On ACEi/ARB, % 81 83 80 0.78
On BB, % 88 97 84 0.10
LVEF at study entry 0.35  0.10 0.31  0.09 0.36  0.09 0.009
LVEDD at study entry 5.5  0.07 5.8  0.07 5.5  0.07 0.04
LVEF at 6 months 0.51  0.11 0.46  0.14 0.53  0.08 0.006
LVEF at 12 months 0.53  0.10 0.47  0.14 0.56  0.07 0.001
DLVEF at 12 months 0.18  0.11 0.17 0.12 0.18  0.10 0.68
Recovered, % 72 59 77 0.13
Values are mean  SD unless otherwise indicated. *The white or other cohort by self-designated
race is predominantly white (65 white and 5 other).
ACEi ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker;
BB ¼ beta-blocker; DBP ¼ diastolic blood pressure; HR ¼ heart rate; LVEDD ¼ left ventricular
end-diastolic diameter; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart
Association; PP ¼ post-partum; SBP ¼ systolic blood pressure.
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907Finally, we compared by race and by initial LVEF the
percentage of subjects who achieved the following
status at the end of study: recovery (last LVEF $0.50),
partial recovery (last LVEF 0.35 to 0.49), no recovery
(last LVEF <0.35), and those with major events
(death, transplantation, or LVAD).
A regression model with LVEF at 12 months as a
continuous outcome and baseline LVEF as a predictor
was used to examine the relationship between these
2 variables. We next used analysis of covariance to
examine how race and baseline LVEF affect the ﬁnal
LVEF at 12 months. When this analysis is signiﬁcant
(p < 0.05), the reported beta coefﬁcient (B) represents
the slope or the number of units the outcome variable
changes with a 1-unit change in the predictor vari-
able. We then examined the univariate effects of
different clinical and demographic factors on LVEF
at 12 months using analysis of variance or regression
models for categorical and continuous variables,
respectively. After their identiﬁcation at 12 months,
the signiﬁcant univariate predictors of LVEF were
included in a multivariate analysis model. In a
multivariate model, B is interpreted as the effect
when holding all other variables constant. These
analyses were performed using SPSS version 21
(IBM, Armonk, New York). Next we examined the
change in LVEF (DLEVF, computed as LVEF at 12
months  baseline LVEF) as a continuous outcome
and tested the effects of baseline LVEF and race on
LVEF change using linear regression models.
The presence of repeated measures of LVEF at 6
and 12 months post-partum allowed us to use both as
outcome measures and evaluate LVEF recovery over
time using a random-effects model that takes into
account the correlation among data collected from
the same subject. We ﬁrst used a univariate analysis
to assess the association of each variable with LVEF
over time (both 6- and 12-month LVEF). After iden-
tifying signiﬁcant univariate predictors of outcome,
we used these factors to build a multivariate mixed-
effects model. The Akaike information criteria were
used for model comparison. Statistical signiﬁcance
was evaluated by likelihood ratio tests and the type I
error controlled at 5%. All statistical analyses were
conducted using R version 3.0.1 (R Foundation for
Statistical Computing, Vienna, Austria).
RESULTS
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS. The
cohort of 100 women included 30% with a self-
designated race as black, 65% as white, and 5% as
other, with a mean age of 30  6 years (range, 18 to 43
years), gravida of 2.8  1.9 (range, 1 to 10), and para of2.2  1.3 (range, 1 to 6). Two women were enrolled on
the day of delivery and the rest post-partum, with
the mean time post-partum at study entry of 31  24
days (range, 0 to 95) (Table 1). The percentage of sub-
jects in each New York Heart Association functional
class (I to IV) at study entry was 12%/46%/25%/17%,
respectively. Baseline vital signs were notable for a
mean systolic blood pressure (BP) of 112  17 mm Hg,
diastolic BP of 70  13 mm Hg, and heart rate of
86 16 beats/min. At the time of study entry, 88%were
receiving beta-blockers, 81% received angiotensin-
converting enzyme inhibitors or angiotensin receptor
blockers, 15% were receiving inotropic therapy, and 2
were on an intra-aortic balloon pump. For the entire
cohort, 10% had a family history of dilated cardiomy-
opathy, 11%were diabetic, 34%were smokers, 45%had
a history of chronic or gestational hypertension, and
5% had a history of autoimmune illness. Only 1 woman
was treated with bromocriptine, and 15% were
breastfeeding at the time of enrollment. Overall, 66
women were enrolled early post-partum (median time
from delivery to study entry, 14 days; 25% and 75%
quartiles: 8 and 24 days, respectively), and 34 women
were enrolled more than 6 weeks post-partum
(median, 59 days; quartile range, 51 to 70 days).
Comparing clinical characteristics by race, black
women were more likely to be enrolled later
FIGURE 1 Event Rate by Baseline LVEF
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The percentage of women who died or underwent LVAD implantation during the ﬁrst
year post-partum. Dashed blue line ¼ women with an initial LVEF $0.30; solid red
line ¼ women with an initial LVEF <0.30. The event rate was signiﬁcantly higher in women
with an LVEF <0.30, p ¼ 0.004. LVAD ¼ left ventricular assist device; LVEF ¼ left
ventricular ejection fraction.
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908(42  25 days post-partum to study entry for black
women vs. 26  22 days for white or other; p ¼ 0.002)
and had a signiﬁcantly lower LVEF at study entry
(0.31  0.09 mean LVEF at study entry for black
women vs. 0.36  0.09 for white or other; p ¼ 0.009).
Black women were also more likely to have a history
of hypertension (70% vs. 34%; p ¼ 0.002) and a
higher mean diastolic BP at study entry (76 
12 mm Hg vs. 68  13 mm Hg; p ¼ 0.009).
Medical therapy (percentage receiving angiotensin-
converting enzyme inhibitors and beta-blockers)
was similar between groups.
EVENT-FREE SURVIVAL. Survival and event data
were available for 97 women at the 6-month and
91 women at the 12-month time points. During the
ﬁrst year post-partum, 6 women experienced 9 major
events: 4 deaths, 4 LVAD implantations, and 1
heart transplantation. Of the 3 women who required
LVAD support early (within the ﬁrst 3 months post-
partum), 2 died while on an LVAD, and 1 underwent
a transplantation. One additional subject required
mechanical support more than 11 months after de-
livery and remained on the LVAD at the time of
12-month follow up. Besides the 6 subjects with
major events, only 3 additional women experienced
cardiac hospitalizations. The event-free survivalrate (survival without LVAD implantation or cardiac
transplantation) at 1 year was 93% (event rate, 7%),
whereas transplantation-free survival (not including
LVAD implantation as an endpoint) was 95%. Event-
free survival was similar between black and white
or other women (p ¼ 0.44), but signiﬁcantly worse
for women with a baseline LVEF <0.30, compared
with those with LVEF $0.30 (1-year event-free
survival rate, 82% vs. 99%; p ¼ 0.004 (Figure 1).
IMPROVEMENT OF LVEF DURING THE FIRST YEAR
POST-PARTUM. For the entire cohort, themean LVEFs
at study entry, 6 months, and 12 months post-partum
were 0.35  0.10, 0.51  0.11, and 0.53  0.10, respec-
tively (Figure 2A). For women enrolled within the ﬁrst
few weeks post-partum, much of the recovery was
noted early, by the 2-month assessment. For women
enrolled early post-partum (n¼ 66), LVEFs at baseline,
2 months, 6 months, and 1 year were 0.35  0.09,
0.48  0.10, 0.53  0.10, and 0.55  0.08, respectively.
For women enrolled later (after 6 weeks post-partum,
n ¼ 34), mean LVEFs at study entry were similar
(0.34  0.10; p ¼ 0.55), but the 6- and 12-month LVEFs
were signiﬁcantly lower (mean LVEF for subjects
enrolled late at 6 months ¼ 0.47  0.12; p ¼ 0.02; 12
months ¼ 0.49  0.14; p ¼ 0.03).
Follow-up LVEFs differed by race at 6 months
(black ¼ 0.46  0.14, white or other ¼ 0.53  0.08;
p¼ 0.006) and 12 months (black¼ 0.47 0.14, white or
other ¼ 0.56  0.07; p ¼ 0.001) (Figure 2B). Women
with more severe LV dysfunction at study entry
(LVEF <0.30) had signiﬁcantly lower LVEFs at 6 and 12
months. For women with an LVEF <0.30 at study en-
try, mean LVEFs at baseline and 6 and 12 months were
0.23  0.05, 0.45  0.14, and 0.46  0.14, respectively;
whereas for womenwith an LVEF at study entry$0.30,
the mean LVEFs at study entry and 6 and 12 months
were 0.39  0.06 (p < 0.001), 0.54  0.08 (p < 0.001),
and 0.56  0.07 (p < 0.001), respectively (Figure 3A).
Womenwith an LVEDD$6.0 cm (n¼ 25) at study entry,
compared with those with an LVEDD <6.0 cm (n ¼ 74),
had a lower LVEF at baseline (mean LVEF at study
entry ¼ 0.31  0.10 vs. 0.36  0.09) (p ¼ 0.04), and at
6 and 12 months (mean LVEF at 6 months ¼ 0.40  0.13
vs. 0.55  0.07; p < 0.001; 12 months ¼ 0.42  0.13 vs.
0.56  0.07; p < 0.001) (Figure 3B).
STATUS AT THE END OF THE STUDY BY RACE AND
INITIAL LVEF. Of the 92 women with either an event
or complete recovery data, poor outcomes were
evident in only 12 (13%), including 6 with major
events and 6 with persistent severe cardiomyopathy.
Partial recovery was evident in 14 women (15%) and
complete recovery in 66 women (72%). Among
women with a baseline LVEF <0.30, 37% achieved a
FIGURE 2 LVEF Over Time Post-Partum
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(A) Overall cohort. LVEF at study entry, 6, and 12 months post-partum for the entire
cohort. (B) By race. The LVEF was signiﬁcantly poorer in black women with PPCM at study
entry (p ¼ 0.009), 6 months (p ¼ 0.006), and 12 months post-partum (p ¼ 0.001).
LVEF ¼ left ventricular ejection fraction; PPCM ¼ post-partum cardiomyopathy.
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909ﬁnal LVEF $0.50, whereas an equal number (37%)
either had an event or a ﬁnal LVEF <0.35. In contrast,
for women with an initial LVEF $0.30, 86% achieved
a ﬁnal LVEF >0.50, whereas only 3% had an event or
ﬁnal LVEF <0.35 (p < 0.001) (Figure 4). Final status
was signiﬁcantly worse in black women (n ¼ 27), as
only 59% achieved a ﬁnal LVEF $0.50 versus 77% of
whites or others (n ¼ 65), whereas 26% of blacks
had either an event or a ﬁnal LVEF <0.35 versus
only 8% of whites or others (p ¼ 0.03). Combining
baseline LVEF and LVEDD allowed a more accurate
prediction of recovery. For women with both an
LVEF $0.30 and an LVEDD <6.0 cm on presentation
(n ¼ 55), 91% recovered to a ﬁnal LVEF $0.50
compared with just 62% of women with only 1 of
these characteristics (n ¼ 26), and 0% (n ¼ 10)
of women with both an LVEF <0.30 and an LVEDD
$6.0 cm (p < 0.00001).
EFFECT OF RACE AND BASELINE LVEF ON LVEF AT
12 MONTHS. Panel A of the Central Illustration shows
the analysis of covariance model examining the joint
effects of baseline LVEF and race on 12-month LVEF
values. Race (B ¼ 31.68; SE ¼ 8.56; p < 0.0001) and
baseline LVEF (B ¼ 0.882; SE ¼ 0.203; p < 0.0001)
were both signiﬁcant predictors of LVEF at 12 months.
In addition, we observed a signiﬁcant interaction
between race and LVEF at baseline (B ¼ 0.789;
SE ¼ 0.25; p ¼ 0.002). In subgroup analyses, we
observed a signiﬁcant association between baseline
LVEF and LVEF at 12 months only in blacks (B ¼ 0.88;
SE ¼ 0.28; p ¼ 0.005) but not in whites and others
(B ¼ 0.093; SE ¼ 0.12; p ¼ 0.44).
EFFECT OF RACE AND BASELINE LVEF ON 12-MONTH
CHANGE IN LVEF. The change in LVEF at 12 months
(DLVEF) was signiﬁcantly associated with baseline
LVEF only (B ¼ 0.52; SE ¼ 0.12; p < 0.001), as a lower
baseline LVEF was associated with more improve-
ment (greater DLVEF). Subset analysis by race
demonstrated that baseline LVEF was signiﬁcantly
associated with DLVEF at 12 months in whites and
others (B ¼ 0.91; SE ¼ 0.12; p < 0.0001) but showed
no association with DLVEF in blacks (B ¼ 0.118;
SE ¼ 0.28; p ¼ 0.68 (Central Illustration, panel B). As
white subjects had a greater tendency to recover, a
lower LVEF was associated with a greater DLVEF at
12 months. In contrast, the DLVEF for black women
appeared independent of their LVEF at study entry.
The DLVEF at 12 months for the overall cohort
appeared similar by race (DLVEF for blacks 0.17  0.12
versus whites 0.18  0.10; p ¼ 0.68) (Table 1). How-
ever, the DLVEF was signiﬁcantly higher for whites
with a lower initial LVEF (DLVEF whites with initial
LVEF <0.35 ¼ 0.25  0.09) compared with whites
FIGURE 3 Initial LVEF and LVEDD and LVEF Over Time
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(A) Initial LVEF <0.30 or $0.30. In women with severe LV dysfunction at study entry,
poorer LV function persists at 6 months (p < 0.001) and 12 months (p < 0.001) post-
partum. (B) Initial LVEDD <6.0 or $6.0 cm. Women with greater LV remodeling at entry
(LVEDD$6.0 cm) demonstrate a lower LVEF at study entry (p¼ 0.04) and less recovery at
6 months (p < 0.001) and 12 months (p < 0.001) post-partum. LV ¼ left ventricular;
LVEDD ¼ left ventricular end-diastolic diameter.
FIGURE 4 Final Status Based on the Initial LVEF
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Comparison of status at the end of the study based on the initial
LVEF. Red column, percentage of women with no recovery
(event or ﬁnal LVEF <0.35); blue column, percentage of women
with partial recovery (ﬁnal LVEF 0.35 to 0.49); purple column,
percentage of women with complete recovery (LVEF $0.50).
Recovery was evident in 86% of women with a baseline
LVEF $0.30, compared with 37% of those with an LVEF <0.30,
p < 0.001. LVEF ¼ left ventricular ejection fraction.
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910with a higher initial LVEF (initial LVEF $0.35,
DLVEF ¼ 0.13  0.08; p < 0.0001) to a much greater
degree than was evident in black women (DLVEF
with initial LVEF <0.35 vs. $0.35 in blacks ¼ 0.18
 0.13 vs. 0.15  0.11; p ¼ 0.47).
UNIVARIATE AND MULTIVARIATE ANALYSES OF
BASELINE PREDICTORS OF LVEF AT 12 MONTHS. On
univariate analysis of the predictors of LVEF at
12 months, initial LVEF at study entry, LVEDD, race,
body mass index (BMI), and time post-partum to
presentation were univariate predictors of subse-
quent LVEF at 12 months (Table 2). There was no
difference in LVEF at 12 months for women who
breastfed (n ¼ 15) compared with those who did not.
There was no apparent difference in 12-month
LVEF for women with a family history of dilated
cardiomyopathy in a primary relative (n ¼ 10) versus
women with no such history. In addition, there
was no apparent difference in recovery on the basis
of multiparity, maternal age, BP, or New York
Heart Association functional class at presentation.
Multivariate analysis demonstrated a signiﬁcant
interaction between black race and baseline LVEF
for their impact on 12-month LVEF (B ¼ 0.72;
SE ¼ 0.23; p ¼ 0.002). This interaction mirrors the
results seen in the linear regression shown in panel A
of the Central Illustration, and supports the observa-
tion that baseline LVEF has a much greater impact on
CENTRAL ILLUSTRATION Myocardial Recovery and Outcomes in Peripartum Cardiomyopathy:
Baseline LVEF, Race, and 12-Month Outcome—Absolute LVEF and Change in LVEF From Baseline
McNamara, D.M. et al. J Am Coll Cardiol. 2015; 66(8):905–14.
A B
(A) Absolute LVEF at 12 months. The y-axis shows the LVEF at 12 months; the baseline LVEF is shown on the x-axis. A signiﬁcant association
was seen in blacks (p < 0.005) but not in whites and others (p ¼ 0.44). (B) Change in LVEF from baseline to 12 months. The change in LVEF is
shown on the y-axis and baseline LVEF is shown on the x-axis. A signiﬁcant association was seen in whites and others (p < 0.0001) but not in
blacks (p ¼ 0.68). LVEF ¼ left ventricular ejection fraction.
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91112-month LVEF in black women than it does in
white women. A multivariate model with all signiﬁ-
cant univariate predictors, which accounted for
the interaction of race and baseline LVEF, demon-
strated that race and LVEDD remained signiﬁcant
predictors of LVEF at 12 months, whereas baseline
LVEF, BMI, and time to presentation were no longer
signiﬁcant (Table 2).
ANALYSIS OF BASELINE PREDICTORS OF LVEF
OVER TIME (COMBINED ENDPOINTS OF 6- AND
12-MONTH LVEFs). Evaluating both 6- and 12-month
LVEFs as combined endpoints (random-effects
model) mirrors the ﬁndings with the 12-month
endpoint alone. Univariate analysis determined that
baseline LVEF (B ¼ 0.44; SE ¼ 0.11; p < 0.001), LVEDD
(B ¼0.83; SE ¼ 0.13; p< 0.001), black race (B¼7.46;
SE ¼ 2.25; p ¼ 0.001), BMI (B ¼ 0.42; SE ¼ 0.15;
p ¼ 0.008), and days post-partum to presentation
(B ¼ 0.11; SE ¼ 0.04; p ¼ 0.02) were again signiﬁcant
predictors. Multivariate analysis accounting for the
interaction of race and baseline LVEF to LVEF over
time (B ¼ 0.54; SE ¼ 0.21; p ¼ 0.01) demonstrated once
more that the most signiﬁcant predictor was LVEDD
(B ¼ 0.68; SE ¼ 0.21; p < 0.0001) followed by race
(B¼18.82; SE¼ 7.19; p¼0.01), whereas baseline LVEF
(B¼0.01; SE¼0.13; p¼0.92), BMI (B¼0.15; SE¼0.13;p ¼ 0.27), and time to presentation (B ¼ 0.07;
SE ¼ 0.0.4; p ¼ 0.18) were not signiﬁcant.
DISCUSSION
In this prospective cohort of women with PPCM
treated with standard heart failure therapy, the
overwhelming majority recovered. In 66 women,
representing 72% of those with a complete assess-
ment, LVEF improved to $0.50 by 12 months.
Indeed, initial echocardiographic assessment delin-
eated a large subset of women (>50% of the total
cohort) presenting without signiﬁcant remodeling
(LVEDD <6.0 cm) or severe LV dysfunction
(LVEF $0.30), in whom the probability of recovery
exceeded 90%. Although this degree of recovery is
encouraging, poor outcomes were still evident in
12 women (13%), including 6 who had a persistent
severe cardiomyopathy and another 6 who either died
or required LVAD implantation by 1 year. Of the
clinical and demographic variables evaluated, LV
remodeling (LVEDD) at entry and black race,
demonstrated the strongest association with lower
LVEF at 12 months post-partum.
There was a clear interaction of race and LV re-
covery over time. Although the mean change in LVEF
TABLE 2 Univariate and Multivariate Analysis Predictors of
12-Month LVEF
Fixed Effect Beta SE p Value
Univariate
Black 8.65 2.44 0.001
Hypertension 0.102 2.39 0.966
Family history of DCM 3.21 4.12 0.44
Diabetes 5.01 3.26 0.16
Breastfeeding 4.94 2.95 0.10
NYHA functional class
II 1.61 3.68 0.66
III 7.21 4.08 0.08
IV 3.73 4.29 0.39
ACEi/ARB 3.91 3.15 0.22
Beta-blocker 1.602 4.17 0.70
Days post-partum at entry 0.11 0.048 0.02
Baseline LVEF 0.481 0.12 <0.0001
LVEDD 0.82 0.15 <0.0001
Age 0.127 0.189 0.50
Parity 0.34 0.94 0.72
SBP, mm Hg 0.016 0.07 0.83
DBP, mm Hg 0.044 0.102 0.66
Heart rate, beats/min 0.08 0.07 0.26
BMI 0.379 0.177 0.04
Multivariate
Baseline LVEF 0.04 0.14 0.79
Baseline LVEDD 0.66 0.17 <0.0001
Black 26.03 7.99 0.002
BMI 0.04 0.15 0.77
Time post-partum 0.06 0.04 0.18
Signiﬁcant univariate predictors of LVEF at 12 months included race, baseline
LVEF, BMI, and days post-partum to study entry. The beta coefﬁcient represents
the slope or the number of units the outcome variable changes with 1-unit change
in the predictor variable. These factors were then included in a multivariate model
that also included an interaction term for race and baseline LVEF (signiﬁcant
interaction of race baseline LVEF for their impact on 12-month LVEF: beta ¼ 0.72;
SE ¼ 0.23; p ¼ 0.002). Only race and LVEDD remain signiﬁcant in the multivariate
analysis.
BMI ¼ body mass index; DCM ¼ dilated cardiomyopathy; other abbreviations as
in Table 1.
McNamara et al. J A C C V O L . 6 6 , N O . 8 , 2 0 1 5
Outcomes in Peripartum Cardiomyopathy A U G U S T 2 5 , 2 0 1 5 : 9 0 5 – 1 4
912at 12 months was similar in black and white subjects,
in blacks, the initial LVEF was predictive of the
12-month LVEF, whereas the change of LVEF was
independent of the initial LVEF. In contrast, in
whites, a lower initial LVEF was associated with
greater improvement at 12 months, and therefore the
LVEF at 12 months appears independent of LVEF at
baseline. As a result, black women presented with a
lower initial LVEF that persisted at 6 and 12 months
post-partum. Black race has been a persistent risk
factor for the development of PPCM in the United
States (16), and the ﬁndings from this analysis sup-
port previous retrospective studies regarding the
impact of race on myocardial recovery in PPCM (13).
Previous studies have suggested that poorer LV re-
covery in black subjects with recent-onset non-
ischemic cardiomyopathy may not be limited toPPCM. In the IMAC2, a prospective study of LV re-
covery in recent-onset nonischemic cardiomyopathy,
poorer recovery was noted in black men, black
women with cardiomyopathy not associated with
pregnancy, and black women with PPCM compared
with white subjects (17,18).
A recent retrospective analysis of a predominantly
African-American cohort reported worse outcomes
than have historically been reported, with high mor-
tality and complete recovery in only 23% of women
(19). In contrast, in the current study, nearly 60% of
black women did achieve complete recovery (ﬁnal
LVEF $0.50). Furthermore, event-free survival did
not differ by race, demonstrating the importance of
prospective data in deﬁning prognosis. Given the 8
patients lost to follow-up, it is possible that the
overall event rate was higher than the 7% reported at
1 year. However, losses to follow-up did not differ by
race and are unlikely to have inﬂuenced this analysis.
STUDY LIMITATIONS. One limitation of the current
study is the variation in the time post-partum to
study entry, from the day of delivery to nearly 3
months post-partum. In general, women who pre-
sented later had a lower LVEF at 12 months post-
partum, but whether this represented a difference in
initial disease severity cannot be determined. Black
women, on average, presented later post-partum, as
more than one-half were enrolled more than 6 weeks
post-partum comparedwith only 22%ofwhite women.
In addition, black women had a much higher preva-
lence of hypertension (70%vs. 34%). Althoughmedical
therapy at entry was similar in racial subsets, whether
the delay in presentation or the increased prevalence
of hypertension among black women contributed to
lower LVEF at entry remains to be determined.
Recently, the use of bromocriptine to inhibit pro-
lactin release has been advocated as a targeted ther-
apy for PPCM (20,21). A 2013 report of a large series
from Germany (22) found that the greatest improve-
ment occurred in PPCM patients receiving a combi-
nation of conventional therapy (beta-blockers and
angiotensin-converting enzyme inhibitors) plus
bromocriptine. However, these investigators did not
ﬁnd any difference in the percentage of PPCM women
who reached full recovery after receiving bromocrip-
tine compared with those who did not. Indeed, the
recovery rate in this German study is comparable to
that of the current investigation on conventional
therapy alone. A randomized trial to address the role
of bromocriptine therapy in PPCM is currently in
progress in Europe.
Breastfeeding prolongs the increase in prolactin in
the post-partum period, and some have advocated
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The majority of
women presenting with PPCM recover myocardial function
completely with conventional heart failure therapy during the
ﬁrst year post-partum. Women with more severe LV dysfunction
or greater LV remodeling at presentation have less chance of
full recovery.
TRANSLATIONAL OUTLOOK: Given the high rate of recovery
of LV function with conventional therapy alone, additional
studies are needed to identify predictors of poorer outcome as a
target for future trials of novel therapeutic interventions.
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913avoidance of breastfeeding as a recommendation for
PPCM mothers. Given the importance of breastfeed-
ing to infant survival (23) in developing nations, this
prohibition comes at a substantial cost in geographic
areas of Africa, Asia, and the Caribbean, where PPCM
is more prevalent. The immunological, develop-
mental, and nutritional advantages of breastfeeding
over the alternatives are increasingly recognized, and
recommendations limiting this practice would also
have hidden costs in more developed countries. In
the current study, breastfeeding was not associated
with any diminishment of recovery, and a previous
retrospective Internet-based study suggested better
outcomes in women who breastfed compared with
those who did not (24). The absence of a hazard for
breastfeeding in IPAC suggests a relatively weaker
inﬂuence of prolactin or prolactin metabolites in the
pathogenesis of PPCM than has been currently
postulated and supports the need for additional study
before solidifying recommendations of breastfeeding
for PPCM mothers.
Although genetic predispositions have been
increasingly recognized as a risk factor for the
development of PPCM (25), the role of genetics for
predicting subsequent recovery remains unknown. A
family history of dilated cardiomyopathy in IPAC did
not predict a poorer subsequent recovery. The small
percentage of women (10%) reporting a family history
likely underestimates the importance of genetics in
the development of PPCM. Future analysis through
molecular diagnostics will help to clarify the role of
genetic predisposition, both for the development of
PPCM and in predicting subsequent recovery.
CONCLUSIONS
The results of the prospective IPAC study demon-
strated signiﬁcant recovery in the majority of women
with PPCM and should be very encouraging to
women presenting with this disorder and to theirphysicians. Unfortunately, adverse outcomes remain
unacceptably high, with 6% dead, having undergone
transplantation, or on an LVAD at 1 year, and
more than 20% left with some degree of chronic car-
diomyopathy. Black women, already at greater risk of
the development of this disorder, demonstrated a
lower mean LVEF, both at presentation and 12
months post-partum. There remains a great need for
more targeted therapies to improve outcomes in
those women whose probability of recovery on con-
ventional therapy is diminished. A poor LVEF at
presentation (<0.30) and a greater degree of LV
dilation (LVEDD $6.0 cm) appear to predict poorer
subsequent recovery with conventional therapy. Tri-
als that target PPCM women with these 2 character-
istics may permit a better assessment of novel
therapeutic interventions.
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